Effect of GnRH Agonist on Endometriosis Cysts
Effect of GnRH Agonist Administration on Decreasing VAS, Estradiol, and Anti Mullerian Hormone in Endometriosis Cyst Patients
This study tests if a new medication can help women aged 18 to 40 with endometriosis cysts feel less pain and have fewer side effects before and after surgery.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 32 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | Female |
| Sponsor | Rumah Sakit Pusat Angkatan Darat Gatot Soebroto Academic / other |
| Locations | 1 site (Jakarta) |
| Trial ID | NCT06525155 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of triptorelin embonate, a GnRH agonist, in treating endometriosis cysts in women aged 18 to 40. Participants will be divided into two groups, receiving either two doses before surgery and one after, or just one dose after surgery. The study will evaluate pain relief using a visual analogue scale and measure hormone levels at specified intervals. The goal is to determine if a longer dosing interval can improve patient compliance and reduce side effects.
Who should consider this trial
Good fit: Ideal candidates are females aged 18 to 40 diagnosed with endometriosis cysts who have regular menstrual cycles.
Not a fit: Patients who have used hormonal contraception or GnRH agonists in the last three months, or those with certain medical histories, may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a more effective and patient-friendly approach to managing endometriosis symptoms.
How similar studies have performed: Previous studies have indicated that extended dosing intervals of triptorelin may be effective, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female subjects aged 18 to 40 years. * The subjects was diagnosed with endometriosis cysts. * Willing to participate in research and sign informed consent before all research-related activities begin. * Regular menstruation (within 25 - 35 day intervals) in the last 3 months before the study was conducted. Exclusion Criteria: * The patient used hormonal contraception in the last 3 months prior to the study. * Using a GnRH agonist within the past 3 months. * Using the hormone progesterone within the last 3 months * Pregnancy, breastfeeding females * History of osteoporosis * History of blood clotting disorders * History of heart and blood vessel disorders
Where this trial is running
Jakarta
- Department of Obstetrics and Gynecology Central Army Hospital Gatot Soebroto — Jakarta, Indonesia (Recruiting)
Study contacts
- Principal investigator: Surya A Pramono, Sp.OG., Subsp.FER, MD — Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
- Study coordinator: Surya A Pramono, Sp.OG., Subsp.FER, MD
- Email: suryaadipramono230781@gmail.com
- Phone: +6282145122104
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.